Cefuroxime detailed information

Cefuroxime detailed information

Clinical data
Routes of administration	oral, intramuscular, intravenous
ATC code	J01DC02 (WHO)
Pharmacokinetic data
Bioavailability	37% on empty stomach, up to 52% if taken after food
Metabolism	axetil moiety is metabolized to acetaldehyde and acetic acid
Elimination half-life	80 minutes
Identifiers
IUPAC name 4-(carbamoyloxymethyl)-8- [2-(2-furyl)-2-methoxyimino-acetyl]amino -7-oxo- 2-thia-6-azabicyclo[4.2.0]oct -4-ene-5-carboxylic acid
CAS Number	55268-75-2
PubChem CID	41375
DrugBank	APRD00285
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C16H16N4O8S
Molar mass	424.386 g/mol

WikiDoc Resources for Cefuroxime detailed information
Articles
Most recent articles on Cefuroxime detailed information Most cited articles on Cefuroxime detailed information Review articles on Cefuroxime detailed information Articles on Cefuroxime detailed information in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Cefuroxime detailed information Images of Cefuroxime detailed information Photos of Cefuroxime detailed information Podcasts & MP3s on Cefuroxime detailed information Videos on Cefuroxime detailed information
Evidence Based Medicine
Cochrane Collaboration on Cefuroxime detailed information Bandolier on Cefuroxime detailed information TRIP on Cefuroxime detailed information
Clinical Trials
Ongoing Trials on Cefuroxime detailed information at Clinical Trials.gov Trial results on Cefuroxime detailed information Clinical Trials on Cefuroxime detailed information at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Cefuroxime detailed information NICE Guidance on Cefuroxime detailed information NHS PRODIGY Guidance FDA on Cefuroxime detailed information CDC on Cefuroxime detailed information
Books
Books on Cefuroxime detailed information
News
Cefuroxime detailed information in the news Be alerted to news on Cefuroxime detailed information News trends on Cefuroxime detailed information
Commentary
Blogs on Cefuroxime detailed information
Definitions
Definitions of Cefuroxime detailed information
Patient Resources / Community
Patient resources on Cefuroxime detailed information Discussion groups on Cefuroxime detailed information Patient Handouts on Cefuroxime detailed information Directions to Hospitals Treating Cefuroxime detailed information Risk calculators and risk factors for Cefuroxime detailed information
Healthcare Provider Resources
Symptoms of Cefuroxime detailed information Causes & Risk Factors for Cefuroxime detailed information Diagnostic studies for Cefuroxime detailed information Treatment of Cefuroxime detailed information
Continuing Medical Education (CME)
CME Programs on Cefuroxime detailed information
International
Cefuroxime detailed information en Espanol Cefuroxime detailed information en Francais
Business
Cefuroxime detailed information in the Marketplace Patents on Cefuroxime detailed information
Experimental / Informatics
List of terms related to Cefuroxime detailed information

Cefuroxime is a second-generation cephalosporin antibiotic that has been widely available in the USA since 1977. It is also available under the brand name Ceftin. Glaxo Smith Kline sells the antibiotic in Australia (and other countries, such as Israel) under the name Zinnat (R), with the Australian pharmaceutical code of R 47621. In Poland it is produced by the Polish firm Bioton S.A. under the name Biofuroksym®.

According to the package insert supplied with Zinnat, Cefuroxime is manufactured as tablets as well as a sodium salt, the latter designed for medical injection.

Indications

As for the cephalosporins, although as a second-generation it is less susceptible to Beta-lactamase and so may have greater activity against Haemophilus influenzae, Neisseria gonorrhoeae and Lyme disease.

Side effects

Cefuroxime is generally well tolerated and side effects are usually transient. Cefuroxime if taken with food is both better absorbed and less likely to cause its commonest upsets of diarrhea, nausea, vomiting and abdominal pain.

Although there is a widely quoted cross-allergy risk of 10% between cephalosporins and penicillin, an article in the Journal of Family Practice (February 2006) has shown no increased risk for cross-allergy for cefuroxime and several other 2nd generation or later cephalosporins.